Bioentrepreneur | Published:

Academic-industry partnerships 2013

Nature Biotechnology volume 32, page 313 (2014) | Download Citation

Public-private partnerships shrank to 301 deals in 2013, down one-fifth from the year prior. Cancer again predominated (84 deals), with neurology (35 deals) and infectious disease (34 deals) second and third in the rankings (Fig. 1). Harvard University was the most active deal maker (Table 1), but both Johns Hopkins University and KU Leuven broke into the top 5 in 2013. AstraZeneca was the most active pharmaceutical firm (14 deals), whereas GlaxoSmithKline fell from its zenith of 14 deals in 2012 to just 9 last year (Fig. 2).

Figure 1: Deals by business area, 2013.
Figure 1

Percentages rounded. Source: SciBx: Science-Business eXchange

Table 1: Academic-private partnerships 2013
Figure 2: Most active pharmas, 2013.
Figure 2

Takeda also had four deals. Source: SciBX: Science-Business eXchange

Author information

Affiliations

  1. Brady Huggett is Business Editor, Nature Biotechnology

    • Brady Huggett

Authors

  1. Search for Brady Huggett in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2861

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing